ATE272117T1 - Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie - Google Patents

Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie

Info

Publication number
ATE272117T1
ATE272117T1 AT94925523T AT94925523T ATE272117T1 AT E272117 T1 ATE272117 T1 AT E272117T1 AT 94925523 T AT94925523 T AT 94925523T AT 94925523 T AT94925523 T AT 94925523T AT E272117 T1 ATE272117 T1 AT E272117T1
Authority
AT
Austria
Prior art keywords
monocyte
cell line
gene therapy
recombinant cells
macrophage cell
Prior art date
Application number
AT94925523T
Other languages
English (en)
Inventor
Hedi Haddada
Manuel Lopez
Michel Perricaudet
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE272117T1 publication Critical patent/ATE272117T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94925523T 1993-08-25 1994-08-22 Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie ATE272117T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9310222A FR2709309B1 (fr) 1993-08-25 1993-08-25 Compositions cellulaires, préparation et utilisations thérapeutiques.
PCT/FR1994/001019 WO1995006120A1 (fr) 1993-08-25 1994-08-22 Cellules recombinantes de la lignee monocyte-macrophage pour la therapie genique

Publications (1)

Publication Number Publication Date
ATE272117T1 true ATE272117T1 (de) 2004-08-15

Family

ID=9450378

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925523T ATE272117T1 (de) 1993-08-25 1994-08-22 Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie

Country Status (14)

Country Link
US (1) US6210963B1 (de)
EP (1) EP0719332B1 (de)
JP (1) JP3731035B2 (de)
KR (1) KR100392984B1 (de)
AT (1) ATE272117T1 (de)
AU (1) AU698043B2 (de)
CA (1) CA2170159A1 (de)
DE (1) DE69433921T2 (de)
FI (1) FI960855A (de)
FR (1) FR2709309B1 (de)
IL (1) IL110754A (de)
NO (1) NO319990B1 (de)
WO (1) WO1995006120A1 (de)
ZA (1) ZA946264B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
CA2245170A1 (en) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating t cells
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
EP0935471B1 (de) * 1996-10-09 2005-03-09 Oxford Biomedica (UK) Limited Mononukleare phagozyten zur verabreichung von therapeutischen arzneimitteln
US20020068048A1 (en) * 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
GB2345063B (en) * 1997-09-23 2002-07-24 Oxford Biomedica Ltd Method
AU4544600A (en) * 1999-04-06 2000-10-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof
AU2001261737A1 (en) * 2000-05-18 2001-11-26 Genetix Pharmaceuticals, Inc. Methods and compositions for promoting angiogenesis using monocytes
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
WO2003024312A2 (en) * 2001-09-17 2003-03-27 Valeocyte Therapies Llc Cell therapy system
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
AU2003203527A1 (en) * 2002-04-12 2003-10-30 Sumitomo Electric Industries, Ltd. Control of the ratio of lap to lip
RU2377253C2 (ru) * 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
JP2006522022A (ja) 2003-02-14 2006-09-28 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ プロテアソーム干渉に関連する避妊法および組成物
US20080038234A1 (en) * 2004-03-23 2008-02-14 Shuji Hayashi Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
ES2603418T3 (es) * 2006-10-04 2017-02-27 Janssen Pharmaceutica Nv Preparación de células presentadoras de antígeno artificial inactivado y su uso en terapias celulares
WO2008089094A2 (en) 2007-01-12 2008-07-24 The Board Of Trustees Of The University Of Illinois Non-simian cells for growth of porcine reproductive and respiratory syndrome (prrs) virus
JP5546107B2 (ja) * 2008-04-17 2014-07-09 国立大学法人宇都宮大学 ＲＮＡウイルスＢｍＭＬＶ陰性カイコ培養細胞株
EP2248903A1 (de) * 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
SG11201508585PA (en) 2013-04-18 2015-11-27 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP7289289B2 (ja) * 2017-03-28 2023-06-09 ツェンラン・チュー 腫瘍性疾患を治療する方法
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
KR20220097875A (ko) 2019-09-03 2022-07-08 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
MX2023005201A (es) 2020-11-04 2023-06-28 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
CN114657143B (zh) * 2022-03-11 2022-10-25 西安电子科技大学 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
CA1340565C (en) * 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
JPH07505045A (ja) * 1991-11-22 1995-06-08 ザ ジェネラル ホスピタル コーポレイション 移植における特異的寛容
US5338165A (en) * 1991-11-25 1994-08-16 Ford Motor Company Automotive fuel pump with modular pump housing
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
US5436151A (en) * 1992-04-03 1995-07-25 Regents Of The University Of Minnesota Method for culturing human hematopoietic stem cells in vitro
DE4219626A1 (de) * 1992-06-16 1993-12-23 Wehling Peter Priv Doz Dr Med Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen
CA2158455C (en) * 1993-03-17 2003-05-27 Nicholas P. Restifo Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors

Also Published As

Publication number Publication date
ZA946264B (en) 1995-03-20
NO319990B1 (no) 2005-10-10
JPH09501837A (ja) 1997-02-25
AU698043B2 (en) 1998-10-22
WO1995006120A1 (fr) 1995-03-02
DE69433921D1 (de) 2004-09-02
JP3731035B2 (ja) 2006-01-05
EP0719332A1 (de) 1996-07-03
FI960855A (fi) 1996-04-23
DE69433921T2 (de) 2006-10-05
KR100392984B1 (ko) 2004-10-20
FI960855A0 (fi) 1996-02-23
NO960743D0 (no) 1996-02-23
NO960743L (no) 1996-03-25
IL110754A (en) 2001-04-30
FR2709309B1 (fr) 1995-11-10
AU7539894A (en) 1995-03-21
CA2170159A1 (fr) 1995-03-02
IL110754A0 (en) 1994-11-11
FR2709309A1 (fr) 1995-03-03
EP0719332B1 (de) 2004-07-28
US6210963B1 (en) 2001-04-03

Similar Documents

Publication Publication Date Title
ATE272117T1 (de) Rekombinante zellen der monozyten-makrophagen zelllinie zur gen-therapie
Koi et al. Tumor cell growth arrest caused by subchromosomal transferable DNA fragments from chromosome 11
AR056723A2 (es) Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid
DE69527540T2 (de) Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen
ATE357509T1 (de) Stimulierung von hämatopoietischen zellen im vitro
ATE265219T1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
TR199801395A2 (xx) Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�.
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE361668T1 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
BR0010563A (pt) Composições isoladas de células da pele e métodos para seu uso
DE69333954D1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
DE69903559T2 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
ES2144626T3 (es) Uso de peptidos de adhesion celular para la modificacion del poder de adhesion de celulas eucarioticas entre si.
DE3855634D1 (de) Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen
DE69328832D1 (de) Zielelektrode zur verhinderung von korrision in elektrochemischen zellen
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
SE8605459D0 (sv) Novel cell growth regulatory factor
Haughn Tumor Cell Growth Arrest Caused by
AU1402495A (en) Use of macrophage depleting agents for prolonging the survival of non-autologus hematopoietic cell transplants and animal model assay systems

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties